Role of androgens in the treatment of patients with low ovarian response

Tomer Feigenberg*, Alex Simon, Assaf Ben-Meir, Yuval Gielchinsky, Neri Laufer

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


The objective of the current report was to provide a summary of knowledge concerning the treatment of women with poor ovarian response with androgens and androgen modulating agents. This involved a review of the literature. The literature search was performed using PubMed. Information concerning the role of androgens and androgen modulating agents in treating women with poor ovarian response is limited. The search of the literature yielded five studies and one case report concerning the treatment of poor responders with androgens. The variations in patient selection, type of androgens employed and the different duration of exposure preclude drawing any definite conclusions. Aromatase inhibitors block the conversion of androgens to oestrogens, thereby promoting an androgen-rich intrafollicular environment. The evidence presented in this review suggests a potential beneficial role for the use of aromatase inhibitors in treating women who have previously experienced failure of standard IVF protocols. The optimal dose and duration of this treatment is yet to be determined. Although the results of studies concerning LH supplementation in poor responders are conflicting, the latest Cochrane review on the use of recombinant LH for ovarian stimulation supports its use in poor responders, based on pooled pregnancy estimates.

Original languageEnglish
Pages (from-to)888-898
Number of pages11
JournalReproductive BioMedicine Online
Issue number6
StatePublished - Dec 2009
Externally publishedYes


  • Androgens
  • Aromatase inhibitors
  • Poor ovarian response


Dive into the research topics of 'Role of androgens in the treatment of patients with low ovarian response'. Together they form a unique fingerprint.

Cite this